Combat Medical highlights patient impact of HIVEC HEAT trial at the American Urological Association Annual Meeting

The ongoing HIVEC HEAT trial aims to generate clinical data to evidence the efficacy of hyperthermic intravesical 80mg mitomycin C chemotherapy for patients with BCG-unresponsive, high risk NMIBC